Chiesi Farmaceutici SpA – Product Pipeline Review –
Q2 2011
Reference Code: GMDHC1324CDB
Publication Date: JUL 2011
Chiesi Farmaceutici SpA – Product Pipeline Review – Q2 2011 GMDHC1324CDB / Published JUL 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1)
Chiesi Farmaceutici SpA – Product Pipeline Review
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 4
List of Figures 4
Chiesi Farmaceutici SpA Snapshot 5
Chiesi Farmaceutici SpA Overview 5
Key Information 5
Key Facts 5
Chiesi Farmaceutici SpA – Research and Development Overview 6
Key Therapeutic Areas 6
Chiesi Farmaceutici SpA – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Chiesi Farmaceutici SpA – Pipeline Products Glance 10
Chiesi Farmaceutici SpA Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Chiesi Farmaceutici SpA–Early Stage Pipeline Products 12
Pre-Clinical Products/Combination Treatment Modalities 12
Chiesi Farmaceutici SpA – Drug Profiles 13
CHF 4226 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
CHF 5074 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Glycopyrrolate 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CHF4227 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CHF 5633 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Chiesi Farmaceutici SpA – Pipeline Analysis 18
Chiesi Farmaceutici SpA – Pipeline Products by Therapeutic Class 18
Chiesi Farmaceutici SpA - Pipeline Products By Target 19
Chiesi Farmaceutici SpA – Pipeline Products by Route of Administration 20
Chiesi Farmaceutici SpA – Pipeline Products by Molecule Type 21
Chiesi Farmaceutici SpA – Recent Pipeline Updates 22
Chiesi Farmaceutici SpA - Dormant Projects 23
Chiesi Farmaceutici SpA – Product Pipeline Review – Q2 2011 GMDHC1324CDB / Published JUL 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2)
Chiesi Farmaceutici SpA – Product Pipeline Review
Chiesi Farmaceutici SpA – Company Statement 24
Chiesi Farmaceutici SpA – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Financial Deals Landscape 30
Chiesi Farmaceutici SpA, Deals Volume Summary, 2004 to YTD 2011 30
Chiesi Farmaceutici SpA, Deals Summary By Region, 2004 to YTD 2011 31
Chiesi Farmaceutici SpA, Deals Summary, 2004 to YTD 2011 32
Chiesi Farmaceutici SpA Detailed Deal Summary 33
Acquisition 33
Chiesi Farmaceutici Acquires Stake In Cornerstone Therapeutics 33
Chiesi Farmaceutici Enters Into An Agreement With Iroko Pharmaceuticals 36
Chiesi Farmaceutici Enters Into Joint Venture With All Gen Pharmaceutical 37
Chiesi Farmaceutici Enters Into An Agreement With NiKem Research 38
Chiesi Farmaceutici Signs Agreement With 3M Drug Delivery Systems 39
Licensing Agreements 40
Phenomix Enters Into Licensing Agreement With Chiesi Farmaceutici 40
Cornerstone Therapeutics Enters Into Licensing Agreement With Chiesi Farmaceutici 42
Nycomed International Management Enters Into Licensing Agreement With Chiesi Farmaceutici 44
Eurand Enters Into Licensing Agreement With Chiesi Farmaceutici 45
Chiesi Farmaceutici Enters Into Licensing Agreement With SALVAT 46
Chiesi Farmaceutici Enters Into A Licensing Agreement With Novartis Pharma 47
Chiesi Farmaceutici Enters Into Licensing Agreement With GB Therapeutics 48
Chiesi Farmaceutici Enters Into Worldwide Licensing Agreement With GB Therapeutics 49
Chiesi Farmaceutici Enters Into A Licensing Agreement With Novartis Pharma For Formoterol pMDI 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 52
Contact Us 52
Disclaimer 52
Chiesi Farmaceutici SpA – Product Pipeline Review – Q2 2011 GMDHC1324CDB / Published JUL 2011
©Global Markets Direct.. This report is a licensed product and is not to be photocopied